慢性肾脏病矿物质与骨异常治疗方案评价标准的建立及应用  

Formulation and Application of Evaluation Criteria for Treatment Regimens of Chronic Kidney Disease-Mineral and Bone Disorder

作　　者：竭小玲 赵霞[1] 毛楠[1] JIE Xiaoling;ZHAO Xia;MAO Nan(The First Affiliated Hospital of Chengdu Medical College,Chengdu,Sichuan,China 610500)

机构地区：[1]成都医学院第一附属医院,四川成都610500

出　　处：《中国药业》2024年第20期119-121,共3页China Pharmaceuticals

基　　金：四川省医学科研课题[S22008]。

摘　　要：目的建立慢性肾脏病矿物质与骨异常(CKD-MBD)治疗方案评价标准。方法根据国内外CKD-MBD相关指南、文献资料及药品说明书建立CKD-MBD治疗方案评价标准。回顾医院2020年收治的512例CKD3a-5D期患者的CKD-MBD治疗方案并进行评价与分析。结果建立的CKD-MBD治疗方案以血清校正钙、血清磷、甲状旁腺激素水平为调控目标,评价标准中包含磷结合剂和活性维生素D使用是否合理。512例患者CKD-MBD治疗方案不合理率为26.95%,其中磷结合剂(醋酸钙片、碳酸司维拉姆片、碳酸镧咀嚼片、碳酸钙D3片)的使用不合理率为16.80%,活性维生素D(骨化三醇软胶囊)的使用不合理率为11.52%。结论建立的CKD-MBD治疗方案评价标准具有针对性强、干预方便、实用性强等优点,可规范CKD-MBD治疗方案,促进临床合理用药。Objective To formulate the evaluation criteria for the treatment regimens of chronic kidney disease-mineral and bone disorder(CKD-MBD).Methods The evaluation criteria for CKD-MBD treatment regimens were formulated based on domestic and international CKD-MBD guidelines,literature and drug instructions.The treatment regimens of 512 patients with CKD-MBD in CKD3a-5D phase admitted to the hospital in 2020 were retrospectively evaluated and analyzed.Results The formulated CKD-MBD treatment regimens were aimed at adjusting the serum corrected calcium,serum phosphorus and intact parathyroid hormone levels,and the criteria mainly involved the rationality evaluation of the use of phosphate binders and active vitamin D.The irrational rate of treatment regimens in 512 patients with CKD-MBD was 26.95%,among which the irrational rate of using phosphate binders(Calcium Acetate Tablets,Sevelamer Carbonate Tablets,Lanthanum Carbonate Chewable Tablets,Calcium Carbonate and Vitamin D3 Tablets)was 16.80%,and that of using active vitamin D(Calcitriol Soft Capsules)was 11.52%.Conclusion The formulated evaluation criteria for CKD-MBD treatment regimens are targeted,convenient and practical,which can be used to standardize CKD-MBD treatment regimens and promote rational clinical drug use.

关 键 词：慢性肾脏病矿物质与骨异常 药物治疗方案 评价标准 合理用药 

分 类 号：R969.3[医药卫生—药理学]